Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
NVCR
NVCR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NVCR News
Soleus Capital Increases Stake in Celcuity
2d ago
Fool
Novocure Price Target Raised to $47 Following FDA Approval
3d ago
stocktwits
U.S. Stocks Decline Midway, Nasdaq Drops Over 350 Points
3d ago
Benzinga
NovoCure Shares Surge Following FDA Approval of Optune Pax
3d ago
Benzinga
HubSpot Reports Strong Q3 Earnings, Shares Surge 9.4%
3d ago
Benzinga
U.S. Stock Futures Rise as Market Sentiment Improves
3d ago
Benzinga
Biotech Stock Soars 25% Following FDA Approval News
3d ago
Barron's
Novocure's Optune Pax FDA Approval Boosts Shares by 23%
3d ago
seekingalpha
Stock Movers: Cisco, AppLovin, Micron, Fastly, Equinix, Rollins, Novocure, and Others
3d ago
Barron's
U.S. Stock Futures Rise as Fastly and Novocure Surge
3d ago
seekingalpha
Fastly Reports Strong Quarterly Earnings Exceeding Expectations
3d ago
Benzinga
U.S. Stock Futures Rise as Jobless Claims Data Looms
3d ago
stocktwits
FDA Approves Optune Pax for Pancreatic Cancer Treatment
3d ago
stocktwits
NovoCure's FDA Approval for Optune Pax Marks Milestone in Cancer Treatment
4d ago
Benzinga
Novocure Receives FDA Approval for New Therapy
4d ago
Businesswire
Optune Pax Receives FDA Approval for Pancreatic Cancer Treatment
4d ago
Newsfilter
Show More News
